5 May 2017 - The National Institute for Health and Care Excellence has published draft guidelines turning down Orexigen’s weight loss pill Mysimba for routine NHS use.

In an Appraisal Consultation Document, the Institute said it does not recommend the drug’s use for managing overweight and obesity in adults with a body mass index of 30 or more, or 27 to 30 with if the patient has one or more weight-related co-morbidities.

Explaining the decision, NICE’s Committee said while Mysimba (naltrexone/bupropion) provides “an innovative option after lifestyle measures have failed, and where orlistat is the only pharmaceutical alternative,” there were concerns “about the validity of the economic analysis and the robustness of the results”.

Read Pharma Times article